ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible.
A first 2023 dose is recommended for all adults aged ≥65 years and at-risk adults aged 18–64 years, 6 months after their most recent COVID-19 vaccine dose. A 2023 dose may be considered for other adults aged 18–64 years.
A second 2023 dose is recommended for all adults aged ≥75 years if 6 months have passed since their last dose.
It is important to note that older vaccine formulations continue to provide strong protection against serious disease.
From 11 December 2023, the following Moderna and Pfizer Monovalent Omicron XBB.1.5 vaccines will be included in the COVID-19 Vaccination Program:
The Pfizer (XBB.1.5) 5-11 years (Light Blue) vaccine is registered for use in people aged 5 years and older.
The Pfizer (XBB.1.5) 12 Years + (Grey) vaccine is registered for use in people aged 12 years and older.
The Moderna (XBB.1.5) 12 Years + (PFS) vaccine is registered for use in people aged 12 years and older.
Onboarding
All sites currently participating in the Program will be onboarded for the vaccines and will receive an email in CVAS.
ATAGI recommendations on Monovalent Omicron XBB.1.5
There has been no change to current booster eligibility:
For primary or additional doses of COVID-19 vaccine, monovalent Omicron XBB.1.5 vaccines are preferred over other vaccines for use in children aged 5 years or older and adults.
People who have not had all recommended 2023 booster dose/s should receive these as soon as possible.
People who have already received the recommended 2023 booster dose/s are not recommended to receive further doses or re-vaccination with an XBB.1.5 vaccine at this time.
ATAGI will provide updated advice in early 2024.
It is important to note that older vaccine formulations continue to provide strong protection against serious disease.
The supply of Moderna Bivalent BA.4-5 12 years+ PFS vaccine is close to expiry (20 December 2023) and soon will no longer be available to order from CVAS.
Last date to order Moderna Bivalent BA.4-5 12 years+ PFS vaccine is Friday 24 November 2023.
Alternative Vaccines
The Pfizer Bivalent BA.4-5 12 years + (grey cap) vaccine will continue to be available for people aged 12 years and over. Novavax can also be used for those patients who are unable or prefer not to have mRNA vaccines. New Moderna and Pfizer Monovalent Omicron XBB.1.5 vaccines will be included in the COVID-19 Vaccination Program from 11 December 2023.
ProQuad® brand no longer on NIP
From November 2023, ProQuad® will no longer be available on the NIP childhood schedule. Providers are advised to use Priorix-Tetra® (measles-mumps-rubella-varicella) at the 18-month schedule point.
The following resources have been updated to reflect this change and will be available to order via the Better Health Center:
Workshop: Overseas Encounters and Catch Ups REGISTER
This webinar will workshop two scenarios of translating overseas vaccination records and developing catch-up schedules. Catch up planning will include both paper-based method and online calculator method. Date: Thursday 30 November Time: 8.00pm – 9.00pm
This webinar will provide an update on Respiratory Syncytial Virus (RSV) burden of disease and discuss the possible impact of prevention. Date: Tuesday 12 December Time: 6.00pm – 8.00pm
News highlights
In case you missed anything, catch up on the latest immunisation news:
From 1 Nov 2023, Shingrix® will replace Zostavax® on the NIP and will be funded for 65+ years, First Nations 50+ years and immunocompromised 18+ years.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…